Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.
OBJECTIVE
Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland.


METHODS
Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention.


RESULTS
In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (< euro 3000/LYG), followed by the statins for secondary prevention (< euro 6500/LYG). Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between euro 12,000 and euro 20,000/LYG).


CONCLUSIONS
Using a comprehensive standardized methodology, cost-effectiveness ratios in this study clearly favored simple medical treatments for myocardial infarction, secondary prevention, angina, and heart failure.
Bennett
Kathleen
K
Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland. bennettk@tcd.ie
Kabir
Zubair
Z
Barry
Michael
M
Tilson
Lesley
L
Fidan
Dogan
D
Shelley
Emer
E
Capewell
Simon
S
D000368:Aged; D000369:Aged, 80 and over; D003327:Coronary Disease / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis / Q000639:trends; D005260:Female; D006801:Humans; D007494:Ireland / Q000453:epidemiology; D008017:Life Expectancy / Q000639:trends*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D055502:Secondary Prevention / Q000191:economics